July 12, 2009

Barcelona: List of ESC Hot Lines, Clinical Trial Updates, and Science Hot Lines ^Reply

Updated and Corrected: The ESC has posted the complete scientific program for the ESC Congress 2009 in Barcelona. Here are the details for Hot Line, Clinical Trial Update, and Science Hot line sessions. You can access the complete program at this link.

(Please note that this information may change over time. You should be sure to check the online ESC program for the latest information.)

Hot Line I 30 Aug 2009 11:00-12:30

Chair: R Ferrari (Ferrara, IT), F J Pinto (Lisbon, PT)
11:00 Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis. G Fowkes (Edinburgh, GB)
11:13 Discussant. C Patrono (Rome, IT)
11:18 A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial. S R Mehta (Hamilton, CA)
11:31 Discussant. F Van de Werf (Leuven, BE)
11:36 Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the PLATelet inhibition and patient Outcomes (PLATO) trial. L C Wallentin (Uppsala, SE)
11:49 Discussant. S D Kristensen (Aarhus N, DK)
11:54 A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke. S J Connolly (Hamilton, CA)
12:07 Discussant. A J Camm (London, GB)
12:12 Clinical Efficacy and Safety of Otamixaban, an Intravenous, Selective Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute Coronary Syndromes: Results of SEPIA-ACS1 TIMI 42. M Sabatine (Boston, US)
12:25 Discussant. H D White (Auckland, NZ)

Hot Line II 31 Aug 2009 11:00-12:30

Chair: C Di Mario (London, GB), J J Bax (Leiden, NL)

11:00 Immediate angioplasty versus ischemia-guided management after thrombolysis for ST-segment elevation myocardial infarction in areas with very long transfers: The NORDISTEMI study. S Halvorsen (Oslo, NO)
11:13 Discussant. FWA Verheugt (Amsterdam, NL)
11:18 Unprotected left main revascularization in patients with acute coronary syndromes. GRACE left main study. G Montalescot (Paris, FR)
11:31 Discussant. C W Hamm (Bad Nauheim, DE)
11:36 Primary angioplasty versus fibrinolysis in the very elderly. The TRIANA Study. H Bueno (Madrid, ES)
11:49 Discussant. D Dudek (Krakow, PL)
11:54 Routine upfront abciximab versus standard peri-procedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock. The PRAGUE-7 Study. P Widimsky (Praha 10, CZ)
12:07 Discussant. A Lafont (Paris Cedex 15, FR)
12:12 Randomized trial of 3-limus agent-eluting stents with biodegradable or permanent polymer coating. ISAR-TEST-4 study.. J Mehilli (Munich, DE)
12:25 Discussant. AD Kugelmass (Detroit, US)

Hot Line III 01 Sep 2009 11:00-12:30

Chair: P Puska (Helsinki, FI), M Komajda (Paris, FR)
11:00 Effects of Valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events (KYOTO Heart Study). H Matsubara (Kyoto, JP)
11:10 Discussant. F Ruschitzka (Zurich, CH)
11:15 Effects of Rolofylline in Patients with Acute Heart Failure Syndrome and Renal Impairment: Findings from the PROTECT- Study. M Metra (Brescia, IT)
11:25 Discussant. M Jessup (Philadelphia, US)
11:30 A randomized evaluation of irbesartan versus placebo in patients with Atrial Fibrillation (factorial design of ACTIVE Program). S Yusuf (Hamilton, CA)
11:40 Discussant. J Brugada Terradellas (Barcelona, ES)
11:45 European CRT Survey. N Bogale (Stavanger, NO)
11:55 Discussant. J C Daubert (Rennes, FR)
12:00 Prevention of Sudden Cardiac Death in Post Myocardial Infarction Patients: Risk Stratification, ICD Therapy Penetration and Related Longterm Outcome: Final Results of the German PreSCD II Registry. H Voeller (Rudersdorf, DE)
12:10 Discussant. P E Vardas (Heraklion, GR)
12:15 Reduction in the risk of heart failure with preventive cardiac resynchronization therapy: MADIT-CRT Trial. A J Moss (Rochester, US)
12:25 Discussant. G Breithardt (Munster, DE)

Clinical Trial Update I 30 Aug 2009 14:00-15:30

Chair: P Ponikowski (Wroclaw, PL), F-T Chiang (Taipei, TW)
14:00 B-CONVINCED. Beta-blocker CONtinuation Versus INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. G Jondeau (Paris, FR)
14:10 Discussant. K Swedberg (Goteborg, SE)
14:15 The impact of achieved heart rate and reduction in heart rate on cardiovascular outcomes: an analysis of the Ivabradine arm of the BEAUTIFUL trial. K M Fox (London, GB)
14:25 Discussant. M Boehm (Homburg/Saar, DE)
14:30 Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. A P Maggioni (Florence, IT)
14:40 Discussant. HJGM Crijns (Maastricht, NL)
14:45 Heart failure events assessment in the Rosiglitazone Evaluation for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD). M Komajda (Paris, FR)
14:55 Discussant. K Dickstein (Stavanger, NO)
15:00 Characteristics of patients enrolled in the Predictors of Response to CRT (PROSPECT) trial: comparison of subgroups according to extent of LV reverse remodeling. RJ van Bommel (Leiden, NL)
15:10 Discussant. C Linde (Stockholm, SE)
15:15 Cardiac Resynchronization Therapy Induces Major Structural and Functional Reverse Remodeling In Mild Heart Failure. 24 month results of the REVERSE trial. S Ghio (Pavia, IT)
15:25 Discussant. J G F Cleland (Kingston upon Hull, GB)

Clinical Trial Update II 31 Aug 2009 14:00-15:30

Chair: A G Fraser (Cardiff, GB), C Yancy (Dallas, US)
14:00 The risk of cardiovascular event for patients treated with clopidogrel or prasugrel in combination with a Proton Pump Inhibitor: Results from the TRITON-TIMI 38 Trial. M O’Donoghue (Boston, US)
14:10 Discussant. K Huber (Vienna, AT)
14:15 Effect of rosiglitazone on coronary events in the RECORD study. J J V McMurray (Glasgow, GB)
14:25 Discussant. B Charbonnel (Nantes, FR)
14:30 Effect of ivabradine on cardiovascular outcomes in patients with stable CAD and LV dysfunction with limiting angina: a subgroup analysis of the BEAUTIFUL trial. R Ferrari (Ferrara, IT)
14:40 Discussant. G Heusch (Essen, DE)
14:45 Randomized evidence on Rosuvastatin for primary prevention in individuals 70 years of age or older. JUPITER. R Glynn (Boston, US)
14:55 Discussant. P G Steg (Paris Cedex 18, FR)
15:00 International impact of atherothrombotic vascular disease and events: 3-year data from the REACH Registry. M Alberts (Chicago, US)
15:10 Discussant. N Danchin (Paris, FR)
15:15 Nonfasting cholesterol and triglycerides, myocardial infarction, and early death. Copenhagen City Heart. B G Nordestgaard (Copenhagen, DK)
15:25 Discussant. V Fuster (New York, US)

Clinical Trial Update III Date: 02 Sep 2009 08:30-10:00

Chair: A A Bove (Philadelphia, US), J L Zamorano Gomez (Madrid, ES)
08:30 Impact of bleeding types on mortality after PCI: Results from a patient-level pooled analysis of the REPLACE-2, ACUITY and HORIZONS trials. R Mehran (New York, US)
08:40 Discussant. W Wijns (Aalst, BE)
08:45 Comparison between the effects of dabigatran versus warfarin in Vitamin K antagonist naïve and experienced patients with atrial fibrillation in the the RE-LY Trial. M D Ezekowitz (Wynnewood, US)
08:55 Discussant. J-P Collet (Paris, FR)
09:00 Clinical outcome after thrombectomy or standard angioplasty in patients with ST elevation myocardial infarction: individual patient-data pooled analysis of 11 randomized trials. ATTEMPT. F Burzotta (Roma, IT)
09:10 Discussant. E Eeckhout (Lausanne, CH)
09:15 Optimal revascularization strategy in patients with three-vessel disease and/or left main disease: The 2 year outcomes of the SYNTAX Trial. AP Kappetein (Rotterdam, NL)
09:25 Discussant. M J Antunes (Coimbra, PT)
09:30 Fractional flow reserve versus angiograhpy for guiding pci – 2 year outcome. N H J Pijls (Eindhoven, NL)
09:40 Discussant. T F Luescher (Zurich, CH)
09:45 Survival in patients with heart failure and preserved versus impaired left ventricular ejection fraction: an individual patient data meta-analysis: MAGGIC. R Doughty (Auckland, NZ)
09:55 Discussant. DM Kaye (Melbourne, AU)

Science Hot Line 31 Aug 2009 11:00-12:30

Chair: A R Pries (Berlin, DE), R De Caterina (Chieti, IT)
11:00 Focal adhesion kinase regulates load-induced PGC-1a expression and mitochondrial biogenesis in mice left ventricle. T Tornatore (Campinas, BR)
11:15 Connexin 43 is fundamental for cytoprotective signal transduction on mitochondrial KATP channels. U C Hoppe (Cologne, DE)
11:30 Myocardial ischemia/reperfusion injury is mediated by leukocytic TLR2 and reduced by systemic administration of a novel anti-TLR2 antibody. F Arslan (Utrecht, NL)
11:45 Exosomes are the active cardioprotective component in MSC secretion. D De Kleijn (Utrecht, NL)
12:00 C-reactive protein and all cause mortality. B G Nordestgaard (Copenhagen, DK)
12:15 Chronic, low dose epoetin-? treatment following PCI significantly improves left ventricular ejection fraction in ischemic heart failure. M W Bergmann (Hamburg, DE)